FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Brain Cancer

Therapeutic area intelligence for Brain Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Phase →

Recent signals(1)

ClinicalJune 26, 2026

Phase III Trial Compares Stereotactic Radiosurgery to HA-WBRT in Brain Cancer Patients

A phase III trial is underway to evaluate the efficacy of stereotactic radiosurgery versus hippocampal avoidance whole brain radiation therapy combined with memantine in patients with small cell lung cancer that has metastasized to the brain.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Brain Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.